Mohammad Naqi

Statistics

Publications

Citations

434

H-Index

Active since

2018

Affiliations

National Institute of Arthritis and Musculoskeletal and Skin Diseases(Current)

National Heart Lung and Blood Institute

National Institutes of Health

Carolina Arthritis Associates

National Institutes of Health Clinical Center

Mohammad Naqi is an author at National Institute of Arthritis and Musculoskeletal and Skin Diseases specializing in systemic lupus erythematosus, autoimmunity, and pharmacology.

Publications per year

2018–2024

Publications

Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

Sarfaraz Hasni, Sarthak Gupta, Michael A. Davis et al. · Nature Communications · 2021 · 197 citations · Full text

Medicine, Immunology, Pharmacology +17

Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus

Philip M. Carlucci, Monica Purmalek, Amit K. Dey et al. · JCI Insight · 2018 · 184 citations · Full text

Life Sciences, Cardiology, Immunology +17

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus

Sarfaraz Hasni, Yenealem Temesgen‐Oyelakin, Michael A. Davis et al. · Annals of the Rheumatic Diseases · 2022 · 25 citations · Full text

Veterinary Medicine, Immunology, Pharmacology +17

The Aconitate Decarboxylase 1/Itaconate Pathway Modulates Immune Dysregulation and Associates with Cardiovascular Disease Markers and Disease Activity in Systemic Lupus Erythematosus

Eduardo Patiño‐Martínez, Shuichiro Nakabo, Kan Jiang et al. · The Journal of Immunology · 2024 · 15 citations · Full text

Life Sciences, Immunology, Pathobiology +17

183 A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus

Sarfaraz Hasni, Sarthak Gupta, Michael A. Davis et al. · Abstracts · 2019 · 13 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

1–5 of 5